Acute non cardiogenic stroke with concomitant cerebral microbleeds
Conditions
Interventions
Cilostazol group:Cilostazol
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Acute ischemic stroke (within 1 month of onset); 2. Non-cardioembolic stroke; 3. Presence of cerebral microbleeds (CMBs) confirmed by susceptibility-weighted imaging.
Exclusion criteria
Exclusion criteria: 1. Previous diagnosis of cerebral amyloid angiopathy (CAA) according to the Boston 2.0 diagnostic criteria; 2. History of intracerebral hemorrhage highly suspected to be caused by CAA-related lobar hemorrhage; 3. Severe adverse reactions (such as active bleeding, severe allergies, etc.) to aspirin or cilostazol in the past, leading to non-compliance with medication; 4. Requirement for combined anticoagulant therapy; 5. Requirement for long-term dual antiplatelet therapy (>1 month).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stroke recurrence during follow-up period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Poor prognosis 3 months after stroke, occurrence of complex vascular events during follow-up, cognitive impairment, and death; | — |
Countries
China
Contacts
Public ContactSheng Zhang
Zhejiang Provincial People's Hospital
Outcome results
None listed